Denmark urges EU to tighten Russian visa restrictions after alleged assassination plot
Denmark has urged European Union countries to introduce tougher travel restrictions on Russian nationals following allegations that Moscow's in...
The World Health Organization is set to recommend weight-loss drugs like Wegovy and Zepbound for treating obesity in adults, marking its first official backing of such medications and signaling a major shift in global health policy.
-The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time, a memo reviewed by Reuters on Thursday shows, marking a shift in its approach to treating the global health problem.
The UN agency also called for strategies to improve access to the treatment in low- and middle-income countries.
More than a billion people now have obesity worldwide, according to the WHO, and around 70% of them live in low and middle-income countries, the World Bank estimates.
The wildly popular obesity drugs - Wegovy developed by Novo Nordisk and Zepbound by Eli Lilly - are known as GLP-1 receptor agonists, which mimic the activity of a hormone that slows digestion and helps people feel full for longer. In clinical trials, people lost 15% to 20% of their body weight, depending on the drug.
The drugs have been launched in the United States and other high-income countries like Germany and Britain.
But they can cost over $1,000 a month, and studies suggest people may have to take the drugs for the rest of their lives to keep the weight off.
The WHO, Eli Lilly and Novo Nordisk were not immediately available for comment.
The WHO's conditional recommendation will be officially released in August, as part of new guidelines on treating obesity. It is also working on separate guidelines for children and adolescents.
Separately, WHO experts will also meet next week to decide whether to include the GLP-1 drugs in the agency's essential medicines list - both to treat obesity and type 2 diabetes.
The WHO's essential medicines list is a catalogue of the drugs that should be available in all functioning health systems, and it can help make drugs more widely available in poorer countries, as experts say happened in 2002 when HIV drugs were included.
In 2023, the experts decided against adding obesity drugs to the list, with WHO saying more evidence was needed on their long-term clinical benefit.
However, in the new memo recommending their use as a treatment, the agency says it supports including them on the list this time round.
Still, the WHO also raises concerns over the cost of the drugs and calls for longer-term studies on cost-effectiveness "across all settings, including LMICs" (low- and middle-income countries).
"The same mechanisms that are used in large-scale medicine access programmes may need to be adopted," to improve access, the WHO adds, such as tiered pricing or pooled procurement.
But it also notes that the active ingredient in one of the newer drugs, semaglutide - used in Novo's Wegovy - comes off patent in some markets next year.
Several companies are planning to launch cheaper generic versions of the drugs then. Liraglutide, the active ingredient in the older generation of drugs, is already available as a lower-cost generic drug, with products approved in the U.S. and Europe, the memo adds.
European leaders backing Ukraine met in Berlin on Thursday 19 November and warned that no peace deal should be settled without them.
Three people have been killed and around 15 injured after Russian ballistic missiles struck three bridges over the Dnipro River in Kyiv, according to the Ukrainian capital’s mayor, Vitali Klitschko.
Azerbaijani President Ilham Aliyev met Vietnamese Prime Minister Le Minh Hung in Hanoi on 20 November, during a visit highlighting the longstanding friendship and growing strategic partnership between the two countries.
Britain and the European Union have reached an agreement to ease trade, expand opportunities for young people and deepen economic ties, in a major step towards rebuilding relations after Brexit.
Georgia has declared 22 November 2026 a national day of mourning following a deadly residential building collapse in the Kvemo Ponichala district of Tbilisi.
For the first time in more than a quarter of a century, the United States can no longer say it has eliminated measles as health experts warn the American outbreak reflects a collapse in trust in vaccines.
A new study in mice suggests the brain’s protective barrier does more than block harmful substances. It also delivers essential proteins from the body, a process that may break down early in Alzheimer’s disease and offer a new target for treatment.
Here's your AnewZ Daily Brief for the 5th of November, as health emergencies, humanitarian crises, political shifts, and cybersecurity threats put governments and essential services under pressure across the globe. Here are five stories worth your attention.
Kazakhstan plans to manufacture 494 types of medicines through eight major investment projects worth a combined $862 million, Health Minister Akmaral Alnazarova announced on 3 November, local media reported.
Dengue fever has killed more people in Bangladesh this year than in the whole of 2025, with October the deadliest month so far, data from Bangladesh's Health Ministry shows.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment